REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION

REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION

Introduction: Discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often results in rebound obesity and excessive weight regain. This review explores the physiological, psychological, and behavioural factors contributing to weight regain after the discontinuation of GLP-1 RAs. Me...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zainab M. Al-Shammaa, Heba M. Attash, Luma Al-Obaidy
Format:	Article
Language:	English
Published:	Education in Action Club 2025-07-01
Series:	Global Journal of Public Health Medicine
Subjects:	glp-1 receptor agonists, weight regain, rebound obesity, discontinuation, lifestyle interventions
Online Access:	https://www.gjphm.org/index.php/gjphm/article/view/336
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

Effect of GLP-1 Receptor Agonists (Liraglutide) on Glycemic Parameters and Circulating miRNA Expression in Type 2 Diabetes Mellitus
by: Aqeel Meer AL-ZAMILY
Published: (2025-06-01)

Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
by: Wenwen Zheng, et al.
Published: (2025-08-01)

Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies
by: Ying Zhong, et al.
Published: (2025-08-01)

Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials
by: Shike Lin, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety
by: Ansel Shao Pin Tang, et al.
Published: (2025-07-01)

Saudi Healthcare Providers’ Perspectives and Clinical Practice of Anti-Obesity Medications: A National Survey
by: Haifa F. AlOtaibi, et al.
Published: (2025-07-01)

Timing of adiposity rebound in children with congenital hypothyroidism diagnosed by newborn screening and treated with Levothyroxine
by: Cecilia Lugarà, et al.
Published: (2025-08-01)

Rebound Thymic Hyperplasia after Chemotherapy in Children with Lymphoma
by: Chih-Ho Chen, et al.
Published: (2017-04-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01)

Systemic semaglutide provides a mild vasoprotective and antineuroinflammatory effect in a rat model of ocular hypertensive glaucoma
by: Zaynab A. Mouhammad, et al.
Published: (2025-07-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
by: T. N. Markova, et al.
Published: (2023-12-01)

Rhabdomyolysis associated with the use of tirzepatide
by: Kunal Sonavane, et al.
Published: (2025-04-01)

The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort
by: Eman A. Toraih, et al.
Published: (2025-04-01)

GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis
by: Mohamed Mohsen Helal, et al.
Published: (2025-08-01)

Weight loss mediates improvement in proinsulin processing during GLP-1 receptor agonist treatment
by: Renjiao Liu, et al.
Published: (2025-07-01)

A Comprehensive Review on the Pharmacokinetics and Drug&minus;Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist
by: Min JS, et al.
Published: (2025-04-01)

Case Report: Rhabdomyolysis following initiation of tirzepatide
by: Jonas Michael Bodanowitz, et al.
Published: (2025-08-01)

IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?
by: D. V. Nebieridze, et al.
Published: (2015-12-01)

How does income inequality affect energy rebound effect? Empirical evidence from China
by: Maliyamu Abudureheman, et al.
Published: (2025-06-01)

Place of imidazoline receptor agonists in the treatment of arterial hypertension
by: D. V. Nebieridze, et al.
Published: (2023-12-01)

A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
by: Jonathan D. Douros, et al.
Published: (2025-10-01)

The role of dulaglutide in the treatment of alcohol use disorder: a case report
by: Olivia Hill, et al.
Published: (2025-05-01)

Health Beliefs and Obesity Bias as Determinants of Attitudes Toward the Rising Tides of GLP-1 Medications: Mounjaro and Ozempic
by: Al-Mahzoum K, et al.
Published: (2025-05-01)

GLP-1 agonists in anaesthetic practice - a review of clinical data and recommendations
by: Natalia Pokrywka, et al.
Published: (2025-07-01)

Neuroprotection through adiponectin receptor agonist: an updated meta-analysis of preclinical Alzheimer’s disease studies
by: Tannaz Novinbahador, et al.
Published: (2025-08-01)

Semaglutide‐Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury
by: Rupayan Kundu, et al.
Published: (2025-08-01)

‘We need more support and doctors that understand the process of tapering …’: A content analysis of free‐text responses to a questionnaire on discontinuing long‐term benzodiazepine receptor agonist use
by: Tom Lynch, et al.
Published: (2024-02-01)

Molecular mechanisms of novel selective glucocorticoid receptor agonist action in breast cancer cells
by: E. M. Zhidkova, et al.
Published: (2024-10-01)

The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes
by: Mizuki Ishiguro, et al.
Published: (2025-08-01)

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis
by: Ruth L. Coleman, et al.
Published: (2025-08-01)

Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations
by: Baixuan Shen, et al.
Published: (2025-08-01)

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
by: A. G. Solodovnikov, et al.
Published: (2020-12-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
by: N. Yu. Velts, et al.
Published: (2024-07-01)

Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes
by: Panupong Hansrivijit, et al.
Published: (2025-06-01)